13589-25-8

Basic information

• Product Name: 2-hydroxy-5-iodobenzoyl chloride
• Synonyms: 2-hydroxy-5-iodobenzoyl chloride;BENZOYL CHLORIDE, 2-HYDROXY-5-IODO-
• CAS NO: 13589-25-8
• Molecular Formula: C₇H₄ClIO₂
• Molecular Weight: 282.46293
• EINECS: -0
• Mol File: 13589-25-8.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-hydroxy-5-iodobenzoyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 2-hydroxy-5-iodobenzoyl chloride(13589-25-8)
• EPA Substance Registry System: 2-hydroxy-5-iodobenzoyl chloride(13589-25-8)

Safety Data

• Hazardous Substances Data: 13589-25-8(Hazardous Substances Data)

Upstream product

• 119-30-2 2-hydroxy-5-iodobenzoic acid 

Downstream Products

• 4068-75-1 methyl 5-iodosalicylate 
• 252651-27-7 N-(2,4-difluorophenyl)-2-hydroxy-5-iodobenzamide 
• 2441-58-9 2-Hydroxy-5-iodo-N-phenyl-benzamide 
• 1280729-51-2 2-hydroxy-5-iodo-N-(4-methoxyphenyl)benzamide 
• 7103-96-0 N-(4-Chloro-phenyl)-2-hydroxy-5-iodo-benzamide 
• 1280729-50-1 2-hydroxy-5-iodo-N-p-tolylbenzamide 

Relevant articles and documents

Halogen Bonding Increases the Potency and Isozyme Selectivity of Protein Arginine Deiminase 1 Inhibitors

Protein arginine deiminases (PADs) hydrolyze the side chain of arginine to form citrulline. Aberrant PAD activity is associated with rheumatoid arthritis, multiple sclerosis, lupus, and certain cancers. These pathologies established the PADs as therapeutic targets and multiple PAD inhibitors are known. Herein, we describe the first highly potent PAD1-selective inhibitors (1 and 19). Detailed structure–activity relationships indicate that their potency and selectivity is due to the formation of a halogen bond with PAD1. Importantly, these inhibitors inhibit histone H3 citrullination in HEK293TPAD1 cells and mouse zygotes with excellent potency. Based on this scaffold, we also developed a PAD1-selective activity-based probe that shows remarkable cellular efficacy and proteome selectivity. Based on their potency and selectivity we expect that 1 and 19 will be widely used chemical tools to understand PAD1 biology.

Screening for covalent inhibitors using DNA-display of small molecule libraries functionalized with cysteine reactive moieties

DNA-encoded chemical libraries are increasingly used to identify leads for drug discovery or chemical biology. Despite the resurging interest in covalent inhibitors, libraries are typically designed with synthon filtered out for reactive functionalities that can engage a target through covalent interactions. Herein, we report the synthesis of two libraries containing Michael acceptors to identify cysteine reactive ligands. We developed a simple procedure to discriminate between covalent and high affinity non-covalent inhibitors using DNA display of the library in a microarray format. The methodology was validated with known covalent and high affinity non-covalent kinase inhibitors. Screening of the library revealed novel covalent inhibitors for MEK2 and ERBB2.

Inhibitors of transcription factor-NF-κB

The present invention provides pharmaceutical compositions of salicylanilide inhibitors of transcription factor NF-κB, and methods for treating diseases in which activation of NF-κB is implicated. More specifically, the present invention provides methods